Polycythemia Vera clinical trials at UCSF

1 research study open to eligible people

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
open to eligible people ages 18 years and up
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
San Francisco, California and other locations

Last updated: May 9, 2023